Psychedelic therapists, pharma collaborate on clinical trial
Mental Health Weekly April 13, 2024 DOI: 10.1002/mhw.34009 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractA leading New York-based organization in psychedelic therapy education is partnering with a biotechnology company to develop an FDA-approved botanical psilocybin drug candidate for an upcoming randomized clinical trial.
Study at a glance
| Characteristics | Randomized Peer reviewed |
|---|---|
| Intervention | botanical psilocybin pharmaceutical candidate |
| Topics | Psilocybin |
| Keywords | Clinical trial Alternative medicine Randomized controlled trial Medical education |
| Key finding | The collaboration aims to produce a botanical psilocybin pharmaceutical for a future randomized clinical trial. |
Abstract
A New York‐based organization, considered a global leader in professional education and training for psychedelic therapy research, is collaborating with a biotechnology company to develop an FDA‐approved botanical psilocybin pharmaceutical candidate to support an upcoming randomized clinical trial.